ORIGINAL ARTICLESTREATMENT OF SARCOIDOSIS: Report of a Controlled Therapeutic Trial
References (5)
- et al.
Lancet
(1962) - et al.
Lancet
(1963)
Cited by (94)
Anti-inflammatory Therapy for Sarcoidosis
2024, Clinics in Chest MedicineEfficacy and safety of infliximab biosimilar Inflectra<sup>®</sup> in severe sarcoidosis
2018, Respiratory MedicineCitation Excerpt :Treatment of sarcoidosis has a multistep approach. Corticosteroids have proved to be effective as initial treatment for sarcoidosis [2–4]. In steroid-refractory cases or in the presence of steroid-associated side effects second-line treatment can be commenced using drugs such as methotrexate, azathioprine, mycophenolate or leflunomide [5–9].
Antiinflammatory Therapy
2018, Sarcoidosis: A Clinician's GuideTreatment of Sarcoidosis
2015, Clinics in Chest MedicineCitation Excerpt :A retrospective study at one institution found that a median dose of 19 mg daily was sufficient to treat acutely decompensated pulmonary sarcoidosis, although the doses used ranged from 10 to 40 mg daily.103 Several early prospective trials with positive results used doses as low as 10 to 20 mg daily.104–106 Therefore, it is not evident that higher doses of corticosteroids offer additional benefit for pulmonary sarcoidosis.
Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis
2020, Respiratory MedicineCitation Excerpt :Therapy with corticosteroids is often started in patients experiencing an intractable cough, dyspnea on exertion or progressive deterioration of pulmonary function [3,10]. The typical initial dose is 20–40 mg prednisone equivalent per day which is subsequently tapered, although there is evidence that a starting dose of 5–15 mg is already clinically beneficial [11–13]. It is estimated that one-third to one-half of patients with sarcoidosis gets treatment with corticosteroids [1].